Luye Pharma Group ( (HK:2186) ) has shared an announcement.
Luye Pharma Group Ltd. has launched its Rotigotine Luye transdermal patch in the UK for treating Parkinson’s disease and restless legs syndrome. This launch marks the first generic transdermal patch in the UK that is bioequivalent to Neupro, offering a smaller size and lower drug load without sodium metabisulfite, a known allergen. The company plans to expand its availability to other countries, leveraging its manufacturing facility in Germany, which specializes in transdermal drug delivery. This move strengthens Luye Pharma’s commitment to CNS treatments and enhances its competitive position in the pharmaceutical industry.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company focused on the development and production of central nervous system (CNS) treatments. The company offers a range of innovative drugs and formulations, including extended-release injectable suspensions and transdermal patches, with a market presence in the United States, China, and Europe.
YTD Price Performance: -5.56%
Average Trading Volume: 100
Technical Sentiment Signal: Strong Buy
Current Market Cap: $842.9M
See more insights into 2186 stock on TipRanks’ Stock Analysis page.